Sarepta Therapeutics Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 68 Posts
1 2 3 ... 5
Sarepta Price Target Raised To $260 From $160 At H.C. Wainwright
Article By: The Fly Friday, December 13, 2019 8:06 AM EST
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Sarepta Therapeutics to $260 from $160 after the FDA reversed course and approved Vyondys 53.
In this article: SRPT
Read
Biotech Scoreboard, November: Gene Therapy Stocks Gain Momentum
Article By: Rod Raynovich Saturday, November 30, 2019 11:38 PM EST
IBB is up 11.2% for November, XBI up 6.3%, but NASDAQ-100 (QQQ) leads up 14.5 %. The big winners for the month include NTLA up 47.24%.
In this article: IBB, QQQ, XBI, SRPT, NTLA, CRSP
Read
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes Monday, September 9, 2019 7:36 PM EST
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
5 Monster Stocks To Watch For Wednesday, August 21
Article By: Michael J. Kramer Wednesday, August 21, 2019 4:32 AM EST
There is the possibility we continue to drift lower on today, as the index works its way towards 2890, in an attempt to refill a gap.
In this article: AMD, JD, BAC, AMZN, SRPT Also: FXI, SPY, VXX
Read
3 Bull Stocks Driving Analysts Crazy
Article By: TipRanks Thursday, September 27, 2018 9:22 AM EST
Take a closer look at these three stocks.
In this article: SRPT, BX, AMZN
Read
Sarepta Price Target Raised To $168 From $83 At Piper Jaffray
Article By: The Fly Wednesday, June 20, 2018 7:15 AM EST
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $168 from $83 after the company presented Phase I/II data on three Duchenne muscular dystrophy boys receiving its micro-dystrophin gene therapy.
In this article: SRPT
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA Friday, May 18, 2018 8:41 PM EST
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Sarepta Drops After U.K. Trial Halt, But Analysts Unconcerned
Article By: The Fly Friday, February 9, 2018 1:50 PM EST
Shares of Sarepta Therapeutics dropped in morning trading following a report that said that the company had halted treatment at sites in the United Kingdom testing its Duchenne muscular dystrophy drug golodirsen.
In this article: SRPT Also: SLDB
Read
E Why Sarepta Therapeutics Inc Looks On Track For A Second DMD Approval
Article By: Samuel Rae Wednesday, October 11, 2017 9:36 AM EST
Here's a look at Sarepta's latest data and where it fits into the company's Duchenne muscular dystrophy (DMD) portfolio. From a trader's perspective, Sarepta looks like it could be a strong pick heading into early 2018 and beyond.
In this article: SRPT
Read
Top Analysts Are Betting On These 5 Hot Stocks For 2018
Article By: TipRanks Sunday, October 8, 2017 3:36 PM EST
Biopharma Sarepta Therapeutics is soaring right now, and top analysts are confident that this stock still has further room to grow. Analysts are predicting that Sarepta can climb by a further 29% over the next 12 months.
In this article: GVA, FOLD, AVGO, SRPT, JD
Read
XBI Breaks Through On A Strong Week For Biotech
Article By: Rod Raynovich Friday, September 29, 2017 7:25 PM EST
The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.
In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI
Read
Sarepta Seen As 'Bargain' For Potential Big Pharma Buyer
Article By: The Fly Thursday, June 8, 2017 3:48 PM EST
While approval for Sarepta Therapeutic's Exondys 51 in the U.S. was controversial, Oppenheimer analyst Hartaj Singh said it has resulted in a "high level" of short interest and the company would be a "bargain" if it is acquired.
In this article: SRPT Also: ALIOF, PFE, JNJ, TKPYY
Read
Biotech Bonanza – Approaching An Inflection Point
Article By: Tarun Chandra, CFA Saturday, May 6, 2017 6:42 PM EST
Biotechs are performing well this year even in an uncertain environment. Policy clarity is important and we may be approaching an inflection point for them to push higher. Investors should maintain exposure to this volatile but promising sector.
In this article: IBB, SPY, XBI, ALXN, AMGN, BIIB, CELG, BIVV, LLY, MRK, PFE, INCY, GILD, SRPT
Read
Options Trading Week In Review
Video By: Jonathan Rose Friday, April 28, 2017 6:30 PM EST
Options analysis, strategies, and a bit of coaching around this week's market action.
In this video: SRG, WTW, SRPT, EHTH, TUR, TTEK, AMD, FB Also: BABA, M
Watch
Sarepta Rises After Analysts Say Buy On Duchenne Drug Upside
Article By: The Fly Thursday, March 2, 2017 11:06 AM EST
Shares of Sarepta Therapeutics are on the rise after Leerink analyst Joseph Schwartz upgraded the stock to Outperform, a buy-equivalent rating, saying that the company's lower estimates seem "achievable" despite headwinds.
In this article: SRPT Also: SHPG
Read
Time To Go Long Brainstorm Cell Therapeutics?
Article By: Jason Napodano Wednesday, January 18, 2017 10:52 AM EST
The similarities in strategy and data between Brainstorm, Bluebird and Sarepta are striking. The discrepancies in valuation present an opportunity.
In this article: BCLI, SRPT, BLUE Also: CUR, D-STEM (DEFUNCT)
Read
1 to 16 of 68 Posts
1 2 3 ... 5